Literature DB >> 6784143

Increased mesolimbic dopamine binding following chronic haloperidol treatment.

R S Kamer, A R Turi, P R Solomon, L J Kaplan.   

Abstract

It is well documented that chronic neuroleptic treatment creates a dopamine receptor supersensitivity in the striatum. The present study examined the effect of chronic neuroleptic treatment on mesolimbic dopamine receptor binding. Rats received either 0.5 mg/kg of haloperidol, 50 mg/kg of sodium phenobarbital, or 0.9% saline daily for 21 days. One week following the last injection, the rats were sacrificed and the septi were removed for the 3H-dopamine binding assay. Haloperidol treatment resulted in a 52% increase in 3H-dopamine binding in the septum, whereas phenobarbital treatment caused no significant change.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6784143     DOI: 10.1007/BF00431827

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  11 in total

1.  Brain neurotransmitter receptors after long-term haloperidol: dopamine, acetylcholine, serotonin, alpha-noradrenergic and naloxone receptors.

Authors:  P Muller; P Seeman
Journal:  Life Sci       Date:  1977-12-15       Impact factor: 5.037

2.  Neuroleptic-induced supersensitivity psychosis.

Authors:  G Chouinard; B D Jones; L Annable
Journal:  Am J Psychiatry       Date:  1978-11       Impact factor: 18.112

3.  The pharmacology of tardive dyskinesias.

Authors:  H L Klawans
Journal:  Am J Psychiatry       Date:  1973-01       Impact factor: 18.112

4.  Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines.

Authors:  D Tarsy; R J Baldessarini
Journal:  Neuropharmacology       Date:  1974-11       Impact factor: 5.250

5.  Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain.

Authors:  D R Burt; I Creese; S H Snyder
Journal:  Science       Date:  1977-04-15       Impact factor: 47.728

6.  Induction of dopaminergic mesolimbic receptor supersensitivity by haloperidol.

Authors:  K L Davis; L E Hollister; W C Fritz
Journal:  Life Sci       Date:  1978-10-16       Impact factor: 5.037

7.  Is there a limbic system equivalent of tardive dyskinesia?

Authors:  K L Davis; G S Rosenberg
Journal:  Biol Psychiatry       Date:  1979-08       Impact factor: 13.382

8.  Dopamine receptor binding: differentiation of agonist and antagonist states with 3H-dopamine and 3H-haloperidol.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Life Sci       Date:  1975-09-15       Impact factor: 5.037

9.  Differential effects of lesions in medial and dorsal raphe of the rat: latent inhibition and septohippocampal serotonin levels.

Authors:  P R Solomon; G L Nichols; J M Kiernan; R S Kamer; L J Kaplan
Journal:  J Comp Physiol Psychol       Date:  1980-02

10.  Dopamine binding following prolonged haloperidol pretreatment.

Authors:  A Hitri; W J Weiner; R L Borison; B I Diamond; P A Nausieda; H L Klawans
Journal:  Ann Neurol       Date:  1978-02       Impact factor: 10.422

View more
  4 in total

1.  Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride.

Authors:  E S Prosser; R Pruthi; J G Csernansky
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Sensitization to haloperidol-induced suppression of milk intake: effect of interdose interval.

Authors:  D L Wolgin; J Moore
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs.

Authors:  N M Rupniak; M D Hall; E Kelly; S Fleminger; G Kilpatrick; P Jenner; C D Marsden
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

4.  The effect of chronic haloperidol treatment on some cardiovascular parameters in cats.

Authors:  G A Bentley; I W Copeland
Journal:  Br J Pharmacol       Date:  1985-11       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.